BRENTWOOD, TN / ACCESSWIRE / November 28, 2023 / Odyssey Behavioral Healthcare, a leading provider of mental health, eating disorder,…
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV,…
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite…
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products…
Cedar Recovery Expands Leadership with Dr. Stuart Ross as Medical Director for Cookeville Office, Bringing Extensive Addiction Medicine Expertise and…
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and…
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target…
Scottsdale, Arizona--(Newsfile Corp. - November 13, 2023) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the…